

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Boehm Michael	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Cardiology (2011-2012) - Astra Zeneca : Cardiology (2011-2012) - Daiichi Sankyo : Cardiology (2011-2012) - Medtronic : Cardiology (2011-2012) - Novartis : Cardiology (2011-2012) - Pfizer : Cardiology (2011-2012) - Servier : Cardiology (2011-2012) - Sanofi Aventis : Cardiology (2011-2012) - Bayer AG : Cardiology (2011-2012) - MSD : Cardiology (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Cardiology (2011-2012) - Medtronic : Cardiology (2011-2012) - Novartis : Cardiology (2011-2012) - Pfizer : Cardiology (2011-2012) - Servier : Cardiology (2011-2012) - Sanofi Aventis : Cardiology (2011-2012) - Bayer AG : Cardiology (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 same relationships as 2012</p>

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Christiaens Thierry	None
Cifkova Renata	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : cardiovascular (2010-2011) - Daiichi Sankyo : cardiovascular (2010) - Medtronic : cardiovascular (2012) - MSD-SP, Boehringer Ingelheim, Bayer : cardiovascular (2010) - Berlin Chemie AG : cardiovascular (2012) - Actavis : cardiovascular (2011) - Merck Sharp & Dohme : cardiovascular (2012) - Zentiva : cardiovascular (2011) - Teva Pharmaceutical Industries : cardiovascular (2011-2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : cardiovascular (2011) - Daiichi Sankyo : cardiovascular (2010) - Novartis : cardiovascular (2012) - Novartis : cardiovascular (2010-2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : cardiovascular (2010) - Krka : cardiovascular (2012) - Krka : cardiovascular (2010-2011) <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 No changes to declare</p> <p>19/05/2013 Same relationships as last year, i.e., no changes to declare.</p>

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
De Backer Guy	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Advisory board (2010-2011-2012) - Merck Sharp & Dohme : Advisory board (2010-2011) - MSD : Advisory board (2012) - Abbott : member of publication committee POWER study (2011) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 No changes to declare</p>
Domiczack Anna F	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Genomics, i.e. N/A (2010) - Servier International : Hypertension/Cardiovascular prevention (2011-2012) - American Heart Association : N/A Journal - Hypertension (2010) - British Heart Foundation, Wellcome Trust, Medical Research Council : N/A (2010) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 Same relationships as 2012 i.e. no changes to declare.</p>
Fagard Robert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Fagard Robert	<ul style="list-style-type: none"> - Servier : Honorarium for manuscript (2011) - Servier : Honorarium for manuscript in Medicographia (2010) <p>Additional Information declared for 2013 January - May</p> <p>03/06/2013 No changes to declare</p>
Galderisi Maurizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Menarini : Cardiac therapy (2010) <p>Additional Information declared for 2013 January - May</p> <p>19/05/2013 No changes to financial interests or positions of influence since my last annual declaration</p>
Grobbee Diederick E	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Roche Pharma : cardiovascular (2011-2012) - Servier : cardiovascular metabolic (2010) - Roche Pharma : cardiovascular metabolic (2010) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Roche Pharma : cardiovascular (2011-2012) - Pfizer : cardiovascular metabolic (2010) - Roche Pharma : cardiovascular risk, diabetes (2010)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Grobbee Diederick E	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Novartis : cardiovascular (2011-2012) - Roche Pharma : Cardiovascular (2011-2012) - Roche Pharma : cardiovascular metabolic (2010) - Pfizer : infectious diseases (2010) - Astra Zeneca : primary and secondary prevention of vascular disease, imaging (2010) - Novartis : renal diabetes (2010) - Pfizer : vaccines (2011-2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Jaarsma Tiny	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Vifor International : IV iron (2010) - Vifor International : IV iron (2010) <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 Guidelines on Hypertension 2013 (TF31)</p> <p>14/05/2013 same relationships as last year i.e. no changes to declare</p> <p>14/05/2013 no changes</p>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - EHRA : arrhythmia management (2010) - BMS : cardiovascular (2011-2012) - Boehringer-Ingelheim : cardiovascular (2011-2012) - Daiichi Sankyo : cardiovascular (2011-2012) - Medtronic : cardiovascular (2011-2012)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> - Pfizer : cardiovascular (2012) - St Jude Medical : cardiovascular (2011-2012) - Sanofi Aventis : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2012) - Meda pharma : cardiovascular (2011-2012) - Merck Sharp & Dohme : cardiovascular (2011-2012) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011-2012) - Boston Scientific : cardiovascular devices (2010) - Medtronic : cardiovascular devices (2010) - St Jude Medical : cardiovascular devices (2010) - Biotronik : cardiovascular devices (2010) - Cordis : cardiovascular devices (2010) - Astra Zeneca : cardiovascular drugs (2010) - Bayer : cardiovascular drugs (2010) - Boehringer-Ingelheim : cardiovascular drugs (2010) - Daiichi Sankyo : cardiovascular drugs (2010) - Sanofi Aventis : cardiovascular drugs (2010) - GlaxoSmithKline : cardiovascular drugs (2010) - BMS/Pfizer : cardiovascular drugs (2010) - Meda pharma : cardiovascular drugs (2010) - Abbott Vascular : cardiovascular drugs (2010) - Takeda Pharmaceuticals : cardiovascular drugs (2010) - Bristol Myers Squibb : cardiovascular drugs (2010) - 3M : cardiovascular drugs (2010)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> - Merck Sharp & Dohme : cardiovascular drugs (2010) - Oxford University Press : heart disease management (2010) - WebMD : heart disease management (2010) - Heart.org : management of heart disease (2010) - Boehringer-Ingelheim : cardiovascular (2012) - Bayer Healthcare : cardiovascular (2012) - Portola Pharmaceuticals : cardiovascular (2012) - BMS / Pfizer alliance : cardiovascular (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - European Union : atrial fibrillation (2010) - Fondation Leducq : atrial fibrillation (2010) - St Jude Medical : cardiovascular (2011-2012) - Sanofi Aventis : cardiovascular (2011-2012) - Meda pharma : cardiovascular (2012) - Meda pharma : cardiovascular (2011) - St Jude Medical : cardiovascular devices (2010) - OMRON Healthcare : cardiovascular devices (2010) - Sanofi Aventis : cardiovascular drugs (2010) - 3M / MEDA Pharma : cardiovascular drugs (2010) - Cardiovascular Therapeutics : cardiovascular drugs (2010) - Deutsche Forschungsgemeinschaft : heart disease (2010) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 Consulting fees and honoraria 3M Medica MEDA Pharma</p>

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<p> AstraZeneca Bayer Healthcare Biosense Webster Boehringer Ingelheim Daiichi-Sankyo German Cardiac Society MEDA Pharma Medtronic Merck MSD Otsuka Pharma Pfizer / BMS sanofi Servier Siemens TAKEDA </p> <p> In addition, I have received travel support for meetings from the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), a registered branch of ESC, and from the German Atrial Fibrillation Competence NETwork (AFNET) </p> <p> Research Grants 3M Medica / MEDA Pharma Cardiovascular Therapeutics Medtronic OMRON SANOFI St. Jude Medical German Federal Ministry for Education and Research (BMBF) Fondation Leducq German Research Foundation (DFG) </p>

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	European Union (EU)
Kjeldsen Sverre Erik	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : Equipment (2010-2011-2012) - Boehringer-Ingelheim : Medical equipment (2010) - Bayer Healthcare : Pharma (2011-2012) - Bayer Healthcare : Pharma (2010) - Takeda Pharmaceuticals : Pharma (2010-2011-2012) - Merck Sharp & Dohme : Pharma (2012) - Serodeus : Pharma (2011-2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Pharma (2010-2011-2012) - Pronova Bioscience : Pharma (2010-2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Norwegian Government : Public Health System (2012) - Norwegian Government : Public Health System (2010-2011) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Norwegian Council for Cardiovascular Diseases : Foundation for Cardiovascular Research (2010-2011-2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Laurent Stephane	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : antihypertensive drugs (2010-2011-2012) - Daiichi Sankyo : antihypertensive drugs (2010-2011-2012) - Novartis : antihypertensive drugs (2010-2011-2012) - Servier : antihypertensive drugs (2010-2011-2012) - Chiesi Pharma : antihypertensive drugs (2010-2011-2012) - Recordati International : antihypertensive drugs (2010-2011-2012)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Laurent Stephane	<ul style="list-style-type: none"> - OMRON Healthcare : Manufacturer, apparatus for blood pressure measurement (2011-2012) - Esaote : Manufacturer, apparatus for blood pressure measurement (2011-2012) - ATCOR : Manufacturer, apparatus for blood pressure measurement (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : antihypertensive drugs (2010-2011-2012) - Esaote : Manufacturer, apparatus for blood pressure measurement (2011-2012) - ATCOR : Manufacturer, apparatus for blood pressure measurement (2011-2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Mancia Giuseppe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : Cardiovascular Area (2010) - Astra Zeneca : Cardiovascular area (2010-2011) - Boehringer-Ingelheim : cardiovascular area (2010-2011) - Novartis : cardiovascular area (2010-2011) - Servier : cardiovascular area (2010-2011) - Sanofi Aventis : cardiovascular area (2010-2011) - Menarini : cardiovascular area (2010-2011) - Takeda Pharmaceuticals : cardiovascular area (2010-2011) - Bayer Schering Pharma : cardiovascular area (2010-2011) - Recordati International : cardiovascular area (2011) - Bayer AG : Cardiovascular area (2012) - Boehringer-Ingelheim : Cardiovascular area (2012) - Daiichi Sankyo : Cardiovascular area (2012) - Medtronic : Cardiovascular area (2012) - Novartis : Cardiovascular area (2012) - Servier : cardiovascular area (2012)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Mancia Giuseppe	<ul style="list-style-type: none"> - Menarini : Cardiovascular area (2012) - Takeda Pharmaceuticals : cardiovascular area (2012) - Recordati International : cardiovascular area (2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 Position: (instead of the position which appears now):</p> <p style="padding-left: 40px;">Emeritus Professor, University of Milano-Bicocca, Milano, Italy</p> <p style="padding-left: 40px;">Director, Center of Epidemiology and Clinical Trials, IRCCS Istituto Auxologico Italiano, Milano, Italy</p>
Manolis Athanasios John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : Hypertension, (2010-2011-2012) - Menarini : hypertension, heart failure (2010-2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : AF (2010-2011-2012) - Boehringer-Ingelheim : AF (2010-2011-2012) - GlaxoSmithKline : Coronary Heart Disease (2010-2011-2012) - Servier : Heart Failure (2010-2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 No new information</p>

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Narkiewicz Krzysztof	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Hypertension (2010-2011-2012) - Daiichi Sankyo : Hypertension (2010-2011-2012) - Medtronic : Hypertension (2011-2012) - Novartis : Hypertension (2010-2011-2012) - Servier : Hypertension (2010-2011-2012) - Sanofi Aventis : Hypertension (2010-2011) - Menarini : Hypertension (2010-2011-2012) - Merck Sharp & Dohme : Hypertension (2010-2011) - Bayer Schering Pharma : Hypertension (2010-2011) - Krka : Hypertension (2010-2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>17/05/2013 Same relationships as reported previously, i.ed. no changes to declare.</p>
Nilsson Peter M	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novo Nordisk : Diabetes treatment (2011-2012) - Boehringer-Ingelheim : linagliptin (2011-2012) - Asstrazeneca : Saxagliptin (2011-2012) - Merck Sharp & Dohme : sitagliptin, anacetrapib (2010-2011-2012) - Novartis : Vildagliptin (2011-2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : vildagliptin (2010-2011-2012)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Nilsson Peter M	<ul style="list-style-type: none"> - Boehringer-Ingelheim : linagliptin (2010) - Astra Zeneca : saxagliptin (2010) - Pfizer : atorvastatin (2010) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 'I have the same relationships as 2012 i.e. no changes to declare'</p> <p style="padding-left: 40px;">Peter M Nilsson</p> <p>14/05/2013 'I have the same relationships as 2012 i.e. no changes to declare'</p> <p style="padding-left: 40px;">Peter M Nilsson</p>
Redon Josep	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Boehringer-Ingelheim : Antihypertensive drugs (2011) - Novartis : Antihypertensive drugs (2011) - Menarini : Antihypertensive drugs (2011) - MSD : Antihypertensive drugs (2011) - Astra Zeneca : Diabetes (2012) - Bristol Myers Squibb : Diabetes (2012) - Boehringer-Ingelheim : Hypertension (2012) - Menarini : Hypertension (2012) - MSD : Hypertension (2012) - Daiichi Sankyo : Antihypertensive drugs (2011) - Daiichi Sankyo : Hypertension (2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Ruilope Luis Miguel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Advisor (2012)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Ruilope Luis Miguel	<ul style="list-style-type: none"> - GlaxoSmithKline : Advisor (2012) - Bristol Myers Squibb : Advisor (2012) - Medtronic : Advisor and speaker (2012) - Servier : Advisor and speaker (2012) - Menarini : Advisor and speaker (2012) - Relypsa : Advisor and speaker (2012) - Takeda Pharmaceuticals : Advisor and speaker (2012) - Astra Zeneca : Cardiovascular (2010) - Bayer : Cardiovascular (2010-2011) - Boehringer-Ingelheim : cardiovascular (2011) - Daiichi Sankyo : Cardiovascular (2010-2011) - Medtronic : Cardiovascular (2010) - Novartis : Cardiovascular (2010) - Pfizer : Cardiovascular (2010) - Menarini : Cardiovascular (2010-2011) - Esteve : cardiovascular (2011) - Takeda Pharmaceuticals : Cardiovascular (2010-2011) - Almiral Spain : Cardiovascular (2011) - Ardian : Cardiovascular (2010) - Ardian : catheter mediated renal denervation (2011) - Daiichi Sankyo : Chairman study SEVITENSION (2012) - Relypsa : CKD (2011) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : CKD (2011) - BMS : Diabetes (2010-2011)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Ruilope Luis Miguel	<ul style="list-style-type: none"> - F. Hoffman La Roche Ltd : Member Executive Committee ALEPREVENT study (2012) - Bayer Healthcare : Member Executive Committee ARRIVE study (2012) - Medtronic : renal denervation (2011) - Astra Zeneca : Speaker and Advisor (2012) - Novartis : Speaker and advisor (2012) - Bayer AG : Speaker and Advisor (2012) - Boehringer-Ingelheim : Cardiovascular (2010) - Boehringer-Ingelheim : Cardiovascular (2011) <p>Additional Information declared for 2013 January - May</p> <p>28/05/2013 Similar to the previous one 2012, except that Otsuka is not present.</p>
Schmieder Roland	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Nephrology and Hypertension (2010-2011-2012) - Boehringer-Ingelheim : Nephrology and Hypertension (2010-2011-2012) - Daiichi Sankyo : Nephrology and Hypertension (2010-2011-2012) - Medtronic : Nephrology and Hypertension (2011-2012) - Novartis : Nephrology and Hypertension (2010-2011-2012) - Servier : Nephrology and Hypertension (2010-2011-2012) - Chiesi Pharma : Nephrology and Hypertension (2010) - Berlin Chemie AG : Nephrology and Hypertension (2010-2011-2012) - Takeda Pharmaceuticals : Nephrology and Hypertension (2010-2011-2012) - Bristol Myers Squibb : Nephrology and Hypertension (2010-2011-2012)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Schmieder Roland	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - BMS : Nephrology and Hypertension (2011-2012) - Daiichi Sankyo : Nephrology and Hypertension (2011-2012) - Medtronic : Nephrology and Hypertension (2011-2012) - Novartis : Nephrology and Hypertension (2011-2012) - Deutsche Forschungsgemeinschaft : Nephrology and Hypertension (2010) - BMBF - German Ministry of Research and Education : Nephrology and Hypertension (2010) - BMBF - German Ministry of Research and Education : Nephrology and Hypertension (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 one additional financial Declaration for 2013:</p> <p style="padding-left: 40px;">D - Research Funding Company : Boehringer Ingelheim Product or Therapeutic Area : Nephrology and Hypertension</p>
Sirnes Per Anton	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - NORMA on behalf of Janssen Cilar : Invest fee CANVAS study (2012) - Quintiles on behalf of Novartis : Investig fee CANTOS study (2012) - GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012) - SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012) - Merck Sharp & Dohme : Investigator fee HPS2-THRIVE STUDY (2012) - Boehringer Ingelheim : Investigator Fee Relyable study (2012) - Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012) - Bayer : clinical studies atrial fibrillation investigator fee (ROCKET) (2010)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Sirnes Per Anton	<ul style="list-style-type: none"> - Merck Sharp & Dohme : investgator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2010-2011) - GlaxoSmithKline : investigator fee, clinical study , SCAD (2010-2011) - Sanofi Aventis : investigator fee, clinical study (PALLAS) (2010) - Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2010-2011) - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2010-2011) - Boehringer-Ingelheim : investigator fee, clinicla study, AF (RELY. RELYABLE) (2010) <p>Additional Information declared for 2013 January - May</p> <p style="padding-left: 40px;">No new information</p>
Sleight Peter	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Aliskeren (2011-2012) - Sanofi Aventis : clopidogrel (2011) - Novartis : DSMB (2010) - Novo-Nordisk : DSMB (2010) - Boehringer-Ingelheim : Hypertension Dabigatran (2011-2012) - Novo-Nordisk : Insulin (2011-2012) - Abbott : Lipids (2011-2012) - Genzyme : Lipids (2011-2012) - Boehringer-Ingelheim : occasional speaker fees (2010) - Astra Zeneca : Hypertension (2011-2012) - Merck Sharp & Dohme : Niacin Lipids (2011-2012) <p>Additional Information declared for 2013 January - May</p>

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	28/05/2013 COI same as 2012
Viigimaa Margus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Coagulation (2010-2011-2012) - GlaxoSmithKline : Coagulation (2010-2011-2012) - Servier : Coronary heart disease (2010-2011) - Merck Sharp & Dohme : Dyslipidemia (2010-2011-2012) - Boehringer-Ingelheim : Hypertension (2010-2011-2012) - Menarini : Hypertension (2010-2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 No new information.</p>
Waeber Bernard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Aliskiren (2011-2012) - Servier : Indapamide (2011-2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : atorvastatine (2011-2012) - Astra Zeneca : candesartan (2011-2012) - Sanofi Aventis : irbesartan (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - KaZ Europe : Blood pressure measuring device (2011-2012)

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<p>Additional Information declared for 2013 January - May</p> <p>28/05/2013 Board of the Pfizer Foundation in Switzerland Board of the Swiss Society of Hypertension Co-editor of the Journal Praxis Member of the Board of the journal "Revue médicale suisse" Member of the editorial board of the Journal of Cardiovascular Pharmacology</p>
Zanchetti Alberto	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Cardiovascular (2010-2011-2012) - Novartis : Cardiovascular (2010) - Menarini : Cardiovascular (2010-2011-2012) - CVRx : Cardiovascular (2010-2011-2012) - Recordati International : Cardiovascular (2010-2011-2012)</p> <p>D - Research funding (departmental or institutional). - CVRx : Cardiovascular (2010-2011-2012)</p> <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 Same relationships as 2012 i.e. no changes to declare 14/05/2013 Same relationships as 2012 i.e. no changes to declare</p>
Zannad Faiez	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : adreview (2010) - Novartis : aliskiren (2010-2011-2012) - Alere : BNP (2010) - Takeda Pharmaceuticals : diabetes (2012)</p>

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Zannad Faiez	<ul style="list-style-type: none"> - Pfizer : eplerenone (2010-2011-2012) - Boston Scientific : heart failure (2010-2011-2012) - Servier : heart failure (2010-2012) - St Jude Medical : heart failure (2010) - Biotronik : heart failure (2012) - Bayer Healthcare : heart failure (2010-2011-2012) - Duke University : heart failure and diabetes (2010) - Relypsa : K polymer (2010) - Astra Zeneca : rosuvastatin (2010) - Resmed : sleep apnea (2012) - Takeda Pharmaceuticals : thrombosis, diabetes, heart failure (2010) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Roche Pharma : biomarker (2010-2011) - Roche Diagnostics : biomarker (2012) - BG medicine : Galectin-3 (2010-2011) <p>No additional information for the 2013 January - May period has been submitted</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
<p>Agabiti-Rosei Enrico</p>	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : hypertension, aliskiren (2011-2012) - Recordati International : Hypertension, enalapril + lercanidipine (2011-2012) - Bayer AG : hypertension, nifedipine, telmisartan (2011-2012) - Daiichi Sankyo : hypertension, olmesartan (2011-2012) - Menarini : Hypertension, olmesartan, nebivolol,zofenopril (2011-2012) - Boehringer-Ingelheim : vascular medicine, telmisartan, dabixatran (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Novartis : Hypertension, aliskiren (2011-2012) - Recordati International : Hypertension, enalapril + lercanidipine (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>20/05/2013 same relationships as last year i.e. no changes to declare. enrico agabiti rosei</p>
<p>Ambrosioni Ettore</p>	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Menarini : speaker fees (2011) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 same relationship as 2012 i.e. no changes to declare</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Anker Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer AG : Anti-coagulation in heart failure (2011) - BRAHMS GmbH : Biomarker in heart failure (2011-2012) - BG medicine : Biomarker in heart failure (2011-2012) - Novartis : Cachexia therapy (2011-2012) - GSK : Cachexia therapy (2011-2012) - GTx : Cachexia therapy (2011-2012) - PsiOxus Therapeutics : Cachexia therapy in cancer (2011-2012) - Reata : CKD therapy (2011) - Abbott Vascular : Device heart failure (2012) - Impulse Dynamics : Device in heart failure (2011) - Impulse Dynamics : Device in heart failure (2012) - LoneStar Heart : Device in heart failure (2011-2012) - Abbott Vascular : Device Renal Failure (2011) - Pluristem Therapeutics : DSMB - stem cells for muscle wasting (2012) - Applied Clinical Intelligence, LLC : Endpoint adjudication COPD (2011-2012) - Servier : Heart failure (2012) - Menarini : Heart failure (2012) - Cardiomems : Heart failure (2012) - Bayer AG : Heart failure (2012) - Medical Sensible : Heart failure (2012) - Vifor International : iv Iron therapy for heart failure (2011-2012) - Servier : Ivabradine heart failure (2011) - Relypsa : K+ Resin (2011-2012) - Professional Dietetics / Solartium Dietetics GmbH : Nutrition for Muscle Wasting / Cachexia (2012)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Anker Stefan	<ul style="list-style-type: none"> - Professional Dietetics / Solartium Dietetics GmbH : Nutrition for Muscle Wasting / Cachexia (2011) - Fresenius Nutrition : Pre-Cachexia therapy (2011) - Amgen Inc : RED-HF (2011) - Novartis : SAB heart failure (2012) - Amgen Inc : SAB heart failure (2012) - St Jude Medical : Telemonitoring (2011-2012) - Bosch AG Germany : Telemonitoring (2011-2012) - SHL Telemedicine : Telemonitoring (2011) - Cardiorentis : TRUE-AHF trial, executive committee (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - BRAHMS GmbH : Biomarkers in heart failure (2011) - Metabolic Research srl (Italy) : Cachexia nutrition research (2012) - Novartis : cachexia research (2012) - PsiOxus Therapeutics : Cancer cachexia (2011-2012) - Novartis : CHF therapy development (2011) - Vifor International : CHF therapy development (2011-2012) - Bayer AG : CHF therapy development (2011-2012) - Impulse Dynamics : Heart failure (2012) - Abbott Vascular : Heart failure (2012) - Medical Sensible : Heart failure (2012) - Abbott Nutrition : Nutrition education (2011) <p>Additional Information declared for 2013 January - May</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
	<p>06/06/2013</p> <p>under A:</p> <p>BG Medicine</p> <p>Professional Dietetics / Solartium Dietetics GmbH: now no longer active</p> <p>Amgen Inc: now no longer active</p> <p>GSK: now no longer active</p> <p>Servier</p> <p>Janzen (J&J) = new</p> <p>under D -- research funding</p> <p>PsiOxus: now no longer support</p> <p>Bayer</p> <p>Medical Sensible: now no longer support</p>
Bauersachs Johann	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS (2011-2012) - Daiichi Sankyo : ACS (2011-2012) - Lilly : ACS (2011-2012)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Bauersachs Johann	<ul style="list-style-type: none"> - Bayer : Afib (2011-2012) - Boehringer-Ingelheim : Afib (2011-2012) - Bristol Myers Squibb : Afib (2011-2012) - Actavis : CAD (2011-2012) - Merck Sharp & Dohme : CAD, Afib (2011-2012) - Pfizer : Heart Failure, Afib (2011-2012) - Medtronic : Heart Failure, Hypertension (2011-2012) - Berlin Chemie AG : Hypertension, CAD (2011-2012) - Novartis : Hypertension, Heart Failure (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : Heart Failure (2011-2012) - Pfizer : Heart Failure (2011-2012) - Sanofi Aventis : Heart Failure (2011-2012) - Actavis : Heart Failure, CAD (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>06/06/2013 same relationships as last year i.e. no changes to declare</p>
Brguljan Jana	<p>None</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Caulfield Mark	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : Renal Denervation (2011-2012)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Caulfield Mark	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : a (2011-2012) - Takeda Pharmaceuticals : a (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Hypertension (2011-2012) - Takeda Pharmaceuticals : Hypertension (2011-2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Clement Denis	<p>None</p> <p>Additional Information declared for 2013 January - May</p> <p>15/05/2013 There are no changes compared to 2012.</p>
Coca Antonio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Aliskiren; Valsartan, combos (2011-2012) - Takeda Pharmaceuticals : Azilsartan (2012) - Recordati International : Azilsartan; Lercanidipine; combos (2012) - Sanofi Aventis : Irbesartan, combos (2011) - Chiesi Pharma : Manidipine, Delapril (2011-2012) - Menarini : Nevibolol; Olmesartan, combos (2011-2012) - Ferrer Internacional : Torasemide; CardioIncode microchips (2011-2012) - Esteve : Valsartan, Aliskiren, combos (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 same relationships as last year i.e. no changes to declare</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
de Buyzere Marc	<p>None</p> <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 same relationships as 2012 i.e. no changes to declare</p>
De Geest Sabina M	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : Cancer (2011-2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : transplantation (2011-2012) - Biotest : transplantation (2011-2012)</p> <p>D - Research funding (departmental or institutional). - Novartis : Transplantation (2011-2012) - Roche Pharma : Transplantation (2011-2012) - Astellas : Transplantation (2011-2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Derumeaux Genevieve Anne	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : Bosentan (2011-2012) - Medtronic : CRT (2011) - Toshiba medical imaging : Echocardiography (2011-2012) - Servier : Ivabradine (2011-2012)</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Derumeaux Genevieve Anne	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Benfluorex (2012) - Medtronic : CRT (2011-2012) - Bayer Healthcare : Pulmonary hypertension and heart failure (2011-2012) - Actelion : Pulmonary hypertension and systemic scleroderma (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - BRAHMS GmbH : Biomarkers (2011) - TROPHOS : Cardioprotection (2011) - Astra Zeneca : Cohort of myocardial infarction patients (2011-2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Erdine Serap	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Therapeutic Area (2011-2012) - Daiichi Sankyo : Therapeutic Area (2011-2012) - Novartis : Therapeutic Area (2011-2012) - Abbott Laboratories : Therapeutic Area (2011-2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Farsang Csaba	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Amgen : diabetes (2011-2012) - Servier : hypertension (2011-2012) - Richter G. Rt. Hungary : hypertension (2011-2012) - EGIS Rt. Hungary : hypertension, diabetes (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 Only one change for the year 2013: AMGEN should be omitted. Otherwise use the previous declaration</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
<p>Funck-Brentano Christian</p>	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis CH : Adjudication Committee on an immunosuppressant (2011-2012) - Lundbeck : Cardiac safety of an antidepressant (2011-2012) - Shire HGT : Cardiac safety of an antidiarrheal drug (2012) - Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2011-2012) - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2011-2012) - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2011-2012) - MMV (CH) : Cardiac Safety of an antimalarial drug (2011) - Santhera (CH) : Cardiac Safety of an antimalarial drug (2011) - Sigma Tau : Cardiac Safety of an antimalarial drug (2011) - MMV (CH) : Cardiac Safety of two antimalarial drugs (2012) - Actelion : Consulting on the potential development of a calcium inhibitor (2012) - BMS : Discussion on an educational program for stroke prevention in AF (2012) - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2011) - CEPHALON : DSMB in an oncology phase IIb trial (2011-2012) - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2011) - Intracellular Therapies USA : Psychotropic drug development (2011) - Medco Health Solutions : co-investigator of a phase I study of an iv antiplatelet drug - payment to the hospital (2012) <p>Additional Information declared for 2013 January - May</p> <p>26/05/2013 No new info since my DOI of 27/02/2013</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Gerc Vjekoslav	None
Germano Giuseppe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Servier : Hypertension (2011) - Takeda Pharmaceuticals : Hypertension (2011) - Recordati International : Hypertension (2011) <p>Additional Information declared for 2013 January - May</p> <p>30/05/2013 'same relationships as 2012 i.e. no changes to declare'</p>
Gielen Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Genzyme : Fabry disease (2011) - Astra Zeneca : Lectures 2012 (2012) - Novartis : Heart failure, antihypertensives (2011) <p>No additional information for the 2013 January - May period has been submitted</p>
Gillebert Thierry	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Boehringer-Ingelheim : Afib (2011) - Astra Zeneca : Heart Failure (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Unrestricted grant Asklepios study (2011-2012)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
<p>Gillebert Thierry</p>	<p>- Merck Sharp & Dohme : Unrestricted grant Asklepios study (2011-2012)</p> <p>Additional Information declared for 2013 January - May</p> <p>04/06/2013 none</p>
<p>Haller Hermann</p>	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : hypertension (2011-2012) - Menarini : hypertension (2011-2012) - Amgen : kidney (2011-2012) - BMS : kidney (2011-2012) - Pfizer : kidney (2011-2012) - Sanofi Aventis : kidney (2011-2012) - Roche Pharma : kidney (2011-2012) - Astellas : kidney (2011-2012) - Genzyme : kidney (2011-2012) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : kidney (2011-2012) - Roche Diagnostics : kidney (2011-2012) - Noxxon : kidney (2011-2012) - MedWiss : kidney (2011-2012) - Alexion : kidney (2011-2012) - Phenos : kidney (2011-2012) - Novartis : kidney and hypertension (2011-2012) - Astra Zeneca : kidney and hypertension (2011-2012)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Haller Hermann	<p>- Bayer Schering Pharma : kidney and hypertension (2011-2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- Novartis : Cyclosporin (2011-2012)</p> <p>- Alexion : Eculizimab (2011-2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Hoes Arno	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012)</p> <p>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</p> <p>D - Research funding (departmental or institutional).</p> <p>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>Additional Information declared for 2013 January - May</p> <p>03/06/2013 no changes to declare</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Jordan Jens	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes (2011-2012) - Novartis : Hypertension/ Heart Failure (2011-2012) - Vivus : Obesity (2012) - Riemser : Obesity (2011-2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Kahan Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : CV (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 Please update with new information on the following (no other changes):</p> <p style="padding-left: 40px;">B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p style="padding-left: 40px;">Company : Servier, Celldon Corp, Medtronic</p> <p style="padding-left: 40px;">Product or Therapeutic Area : Cardiovascular</p>
Komajda Michel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - BMS : cardio metabolic (2012) - Sanofi Aventis : cardio metabolic (2012) - Focus : cardiology (2012) - Nile Therapeutics : CDNP (2012) - Servier : Ivabradine (2011-2012) - Duke University : Nesiritide (2011)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Komajda Michel	<ul style="list-style-type: none"> - Johnson & Johnson : Nesiritide (2012) - PLB organisation : organisation (2011) - Menarini : Ranolazine (2011-2012) - Torrent : TRC 4186 (2011) <p>No additional information for the 2013 January - May period has been submitted</p>
Lovic Dragan	<p>None</p> <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 I have nothing to declare, there is no conflict of interest.</p>
Mahrholdt Heiko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Institut für Herzinfarktforschung Ludwigshafen, Germany : Consultant (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Robert Bosch Foundation : Research Grants (2011-2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Olsen Michael Hecht	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Novo Nordisk : Lecture (2012) - Novo Nordic Foundation : Research within cardiovascular target organ damage (2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Ostergren Jan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Novartis : Aliskiren (2011-2012)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
	<p>Additional Information declared for 2013 January - May</p> <p>31/05/2013 No changes to declare for 2013</p>
Parati Gianfranco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Hypertension (2012) - Speaker s fee, Bayer : Hypertension (2011) <p>No additional information for the 2013 January - May period has been submitted</p>
Perk Joep	<p>None</p> <p>Additional Information declared for 2013 January - May</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Polonia Jorge Manuel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Speaker: Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Jaba Recordati, Medinfar, Menarini, Novartis, Sanofi-Aventis, Servier : antihypertensive drugs (several); oral antidiabetic drugs (2011) - Speaker: Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Jaba Recordati, Medinfar, Menarini, Novartis, Sanofi-Aventis, Servier : Antihypertensive drugs and antidiabetic drugs several (2012) <p>Additional Information declared for 2013 January - May</p> <p>20/05/2013 Same relationships as January 2013 i.e. no changes to declare</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Popescu Bogdan Alexandru	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging (2011-2012)</p> <p>Additional Information declared for 2013 January - May</p> <p>03/06/2013 Same relationships as declared on Feb 26, 2013, i.e. no changes to declare.</p>
Reiner Zeljko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulants (2011) - Astra Zeneca : antilipemics (2011-2012) - Pfizer : antilipemics (2011) - Sanofi Aventis : antilipemics (2011) - Abbott Laboratories : antilipemics (2011-2012) - Bayer : Antithrombotics (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Antilipemics (2012) - Merck Sharp & Dohme : Antilipemics (2012) - Merck Sharp & Dohme : antilipemics (2011)</p> <p>Additional Information declared for 2013 January - May</p> <p>31/05/2013 No changes to declare in 2013</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Ryden Lars	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Cardiology; Course organisation, lecture (2011-2012) - Sanofi Aventis : Daibetes and cardiovascular disease. Advisor boards, lecture fees (2011) - BMS : Diabetes and cardiovascular disease. Advisory committee fee (2011-2012) - Astra Zeneca : Diabetes and cardiovascular disease; Advisory Board and occasional lecture fees (2011-2012) - Roche Pharma : Diabetes and cardiovascular disease; Consultant, lecture fees (2011-2012) - Bayer : Diabetes and cardiovascular disease; Lecture fees (2012) - Bayer : Diabetes and cardiovascular disease; Lecture fees (2011) - Amgen : Member DSMB (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Roche Pharma : Diabetes and cardiovascular disease (2012) - Astra Zeneca : Cardiology (2011) - Roche Pharma : Cardiology (2011) <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 I have become honorary member of the Moldavian and the Romanian Societies of Cardiology in April 2013.</p> <p>13/05/2013 Besides the new honorary memberships no further changes,</p>
Sirenko Yuriy	<p>None</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Stanton Alice	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Rox Medical : Cardiovascular Interventions (2011-2012) - Bayer : Cardiovascular Therapeutics (2011) - Boehringer-Ingelheim : Cardiovascular Therapeutics (2011-2012)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Stanton Alice	<ul style="list-style-type: none"> - Daiichi Sankyo : Cardiovascular Therapeutics (2011-2012) - Novartis : Cardiovascular Therapeutics (2011) - Pfizer : Cardiovascular Therapeutics (2011) - Servier : Cardiovascular Therapeutics (2011-2012) - Menarini : Cardiovascular Therapeutics (2011-2012) - Takeda Pharmaceuticals : Cardiovascular Therapeutics (2011-2012) - Bristol Myers Squibb : Cardiovascular Therapeutics (2011) - Sigma Tau : Cardiovascular Therapeutics (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Rox Medical : Cardiovascular Interventions (2012) - Bayer AG : Cardiovascular Therapeutics (2012) <p>Additional Information declared for 2013 January - May</p> <p>20/05/2013 No new information</p>
Struijker-Boudier Harry A J	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Cardiovascular (2011-2012) - Merck-Serono : Cardiovascular (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 No changes to declare</p> <p>14/05/2013 No changes to declare</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Aspirin, Rivaroxaban (2011-2012) - Amgen : Darbopietin (2011-2012) - Servier : Ivabradine, Phase II investigational products (2011-2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, Phase II investigational products (2011-2012) - TIMI group : Rivaroxaban (2011)</p> <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 No new info.</p>
Tsioufis Costas	<p>None</p> <p>Additional Information declared for 2013 January - May</p> <p>15/05/2013 I have received payment of Travel Expenses, Research Grands and Honoraria from Medtronic, St Jude, Novartis, Astra Zeneca, Bayer, Abbott.</p>
van de Borne Philippe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Bayer : small fee for writing a chapter (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Advisory board (2011-2012)</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
van de Borne Philippe	<ul style="list-style-type: none"> - Bayer Schering Pharma : Advisory board (2011-2012) - Astra Zeneca : Chair chronic cardiovascular disease (for the department) (2011-2012) - Boehringer-Ingelheim : Education grant (for the department) (2011) - Medtronic Foundation : Education grant (for the department) (2011) - Daiichi Sankyo : Speakers fee (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Dr . Tagnon fund : Renal denervation (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>28/05/2013 'same relationships as 2012 i.e. no changes to declare'</p> <p>30/05/2013 'same relationships as 2012 i.e. no changes to declare'</p>
Vlachopoulos Charalambos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Statin (2011-2012) - Bayer : Testosterone (2012) <p>Additional Information declared for 2013 January - May</p> <p>05/06/2013 No changes to declare</p>
Volpe Massimo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : aliskiren, valsartan (2011-2012) - Sanofi Aventis : dronedarone (2011-2012)

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
Volpe Massimo	<ul style="list-style-type: none"> - Daiichi Sankyo : olmesartan (2011-2012) - Menarini : olmesartan (2011-2012) - Boehringer-Ingelheim : telmisartan (2011-2012) - Bayer Healthcare : telmisartan (2011-2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Daiichi Sankyo : no specific product (2011-2012) - Novartis : no specific product (2011-2012) <p>Additional Information declared for 2013 January - May</p> <p>31/05/2013 same relationships as 2012 i.e. no changes to declare</p>
Wood David Allan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Kowa : Atherosclerosis (2011) - Astra Zeneca : Crestor - Lipid Modification (2011) - Astra Zeneca : Lipid modification (2012) - Merck Sharp & Dohme : Niacin - Lipid Modification (2011-2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - EMD Communications China : Training Course in Preventive Cardiology (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - European Society of Cardiology : EUROASPIRE IV (2012) - Pfizer : Varenicline - smoking cessation (2011) <p>Additional Information declared for 2013 January - May</p>

Guidelines on Hypertension 2013 (TF31) - Reviewers

Expert	Type of Relationship with Industry
	<p>04/06/2013 Following changes to the List of the ESC bodies membership section:</p> <p>REMOVE: ESC Board Members, ESC Business Model Task Force, ESC Training and Research Grants Committee, Advisory Group for the ESC Cardiovascular Research Foundation, 5th Joint European Task Force on CVD Prevention. ADD: CardioScape, ESC Strategy Committee.</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Siemens Healthcare : CT (2012) - Servier : Imaging (2012) - Guerbet : Imaging (2012) <p>Additional Information declared for 2013 January - May:</p> <p>14/05/2013 Same relationships as last year, nothing new to declare.</p>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2012) - Edwards Lifesciences : transcatheter valve implantation (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2012) - Edwards Lifesciences : transcatheter valve implantation (2012) <p>Additional Information declared for 2013 January - May:</p> <p>13/05/2013 no changes compared to 2012</p>
Bax Jeroen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Farma (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Bax Jeroen	<ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valves (2012) - GE Healthcare : Imaging (2012) - Lantheus Inc : Imaging (2012) - Boston Scientific : Pacing (2012) - Medtronic : Pacing (2012) - St Jude Medical : Pacing (2012) - Biotronik : Pacing (2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Aspirin, rivaroxaban (2012) - Roche Pharma : Dalcetrapib (2012) - Novartis : Heart Failure and elinogrel (2012) - Daiichi Sankyo : Prasugrel (2012) - Eli Lilly : Prasugrel (2012) - Astra Zeneca : Ticagrelor (2012) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2012) <p>Additional Information declared for 2013 January - May:</p> <p>14/05/2013 No additional information to disclose in addition to my February 2013 disclosure</p>
Deaton M Christi	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Deaton M Christi	<p>D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012)</p> <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 Funding from Novo Nordisk has ended, no other changes to report 13/05/2013 no other new information</p>
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012)</p> <p>C - Receipt of royalties for intellectual property. - Astra-Zeneca : Ticagrelor (2012)</p> <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 Only the product of Menarini should be Olmesartan. That is all I can change. Thank you very much.</p>
Fagard Robert	<p>None</p> <p>Additional Information declared for 2013 January - May</p> <p>03/06/2013 No changes to declare</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Ferrari Roberto	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulant and diabetes. Dagabitran (2012) - Medical Trials Analysis : Consultant in Clinical Trials (2012) - Servier : Myocardial ischemia and heart failure. Perindopril, ivabradine, amlodipine, trimetazidine (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Schering-Plough : Anti-platelet agent TRACER (2012) - Fondazione Salvatore Maugeri : General (2012) - Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 No new information</p>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None - Boehringer-Ingelheim : Pradaxa (2012) - Bayer : Rivaroxiban (2012) - Astra Zeneca : Ticagrelor (2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 none</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Hoes Arno	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012)</p> <p>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</p> <p>D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>Additional Information declared for 2013 January - May</p> <p>03/06/2013 no changes to declare</p>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : cardiovascular (2012) - Boehringer-Ingelheim : cardiovascular (2012)</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> - Daiichi Sankyo : cardiovascular (2012) - Medtronic : cardiovascular (2012) - Pfizer : cardiovascular (2012) - St Jude Medical : cardiovascular (2012) - Sanofi Aventis : cardiovascular (2012) - Meda pharma : cardiovascular (2012) - Merck Sharp & Dohme : cardiovascular (2012) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : cardiovascular (2012) - Bayer Healthcare : cardiovascular (2012) - Portola Pharmaceuticals : cardiovascular (2012) - BMS / Pfizer alliance : cardiovascular (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2012) - Sanofi Aventis : cardiovascular (2012) - Meda pharma : cardiovascular (2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 Consulting fees and honoraria 3M Medica MEDA Pharma AstraZeneca Bayer Healthcare Biosense Webster Boehringer Ingelheim Daiichi-Sankyo German Cardiac Society MEDA Pharma</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
	<p>Medtronic Merck MSD Otsuka Pharma Pfizer / BMS sanofi Servier Siemens TAKEDA</p> <p>In addition, I have received travel support for meetings from the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), a registered branch of ESC, and from the German Atrial Fibrillation Competence NETwork (AFNET)</p> <p>Research Grants 3M Medica / MEDA Pharma Cardiovascular Therapeutics Medtronic OMRON SANOFI St. Jude Medical German Federal Ministry for Education and Research (BMBF) Fondation Leducq German Research Foundation (DFG) European Union (EU)</p>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2012)</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Knuuti Juhani	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Vascular inflammation (2012) - Athera : vascular inflammation (2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet agents (2012) - Regado Biosciences : Antithrombotic agents (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antistaphylococcic vaccine (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves (2012) - Medtronic : Cardiac valves (2012) - St Jude Medical : Cardiac valves (2012) - Boston Scientific : Coronary stents (2012) - Siemens Healthcare : Medical imaging (2012) - Johnson & Johnson : Thoracoscopic devices (2012) <p>Additional Information declared for 2013 January - May</p> <p>15/05/2013 same relationships as 2012 i.e. no changes to declare</p>
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : Heart Failure (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Brilique (2012) - Servier : Coversyl (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Lancellotti Patrizio	- Abbott Vascular : MitraClip (2012)
Linhart Ales	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension (2012) - Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012) - GlaxoSmithKline : Atherosclerosis (2012) - Merck Sharp & Dohme : Dyslipidemia (2012) - Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012) - Shire HGT : Fabry disease (2012) - Genzyme : Fabry disease (2012) - Actelion : Pulmonary hypertension (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Shire HGT : Fabry disease (2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Nihoyannopoulos Petros	<p>None</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Piepoli Massimo Francesco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Chiesi Pharma : Anti-dyslipidemic therapy (2012) <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 'same relationships as 2012 i.e. no changes to declare':</p>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - BMS : anticoagulant (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulant (2012) - Respicardia : anticoagulant (2012) - Abbott Vascular : devices (2012) - Amgen : heart failure (2012) - Novartis : heart failure (2012) - Johnson & Johnson : heart failure (2012) - Bayer Healthcare : heart failure (2012) - Vifor Pharma ltd : heart failure (2012) - Corthera : heart failure (2012) - Coridea : heart failure (2012) - Pfizer : heart failure, anticoagulant (2012) - Servier : heart failure, coronary artery disease (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Vifor Pharma ltd : heart failure (2012) <p>Additional Information declared for 2013 January - May</p> <p>14/05/2013 update to DOI 2012: - Abbott Vascular</p>
Sirnes Per Anton	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - NORMA on behalf of Janssen Cilar : Invest fee CANVAS study (2012) - Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Sirnes Per Anton	<ul style="list-style-type: none"> - GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012) - SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012) - Merck Sharp & Dohme : Investigator fee HPS2-THRIVE STUDY (2012) - Boehringer Ingelheim : Investigator Fee Reliable study (2012) - Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012) <p>Additional Information declared for 2013 January - May No additional information for the 2013 January - May period has been submitted</p>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - sanodi-aventis : Dronedarone-antiarrhythmic agent (2012)</p> <p>E - Research funding (personal). - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)</p> <p>No additional information for the 2013 January - May period has been submitted</p>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Aspirin, Rivaroxaban (2012) - Amgen : Darbopietin (2012) - Servier : Ivabradine, Phase II investigational products (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, Phase II investigational products (2012)</p> <p>Additional Information declared for 2013 January - May 13/05/2013 No new info.</p>

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Cardiomems : implanted pulmonary artery pressure sensor (2012) - United Therapeutics : Pulmonary arterial hypertension (2012) - GSK : pulmonary arterial hypertension - ambrisentan (2012) - Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012) - Lilly : pulmonary arterial hypertension - tadalafil (2012) - AOP : Pulmonary arterial hypertension - treprostinil (2012) - Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2012) - Bristol Myers Squibb : thromboembolic disease - Apixaban (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Pulmonary hypertension (2012) - Sanofi Aventis : Thromboembolic disease (2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Wijns William	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - None <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Biosensors : device (2012) - Boston Scientific : device (2012) - Edwards Lifesciences : device (2012) - Medtronic : device (2012) - St Jude Medical : device (2012) - Biotronik : device (2012) - Terumo Inc : device (2012) - Abbott Vascular : device (2012) - Cordis : device (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Wijns William	<ul style="list-style-type: none"> - Orbus Nech : device (2012) - MICELL : device (2012) - Vessix : device (2012) - Tryton : device (2012) - GlaxoSmithKline : drug (2012) - Astra Zeneca : pharma (2012) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Cardio3 Biosciences : cell therapy (2012) - Boston Scientific : device (2012) - Medtronic : device (2012) - St Jude Medical : device (2012) - Biotronik : device (2012) - Abbott Laboratories : device (2012) - MICELL : device (2012) - Therabel : drug (2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet drug (2012) - Eli Lilly : Antiplatelet drug (2012) - Abbott : Stent (2012) - Biosensors : Stent (2012) - Boston Scientific : Stent (2012) - Medtronic : Stent (2012) - Biotronik : Stent (2012) - Cordis : Stent (2012)

Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Edwards Lifesciences : TAVI (2012) D - Research funding (departmental or institutional). - St Jude Medical : OCT (2012) - Abbott : Stent (2012) - Biosensors : Stent (2012) - Medtronic : Stent (2012) - Biotronik : Stent (2012) - Cordis : Stent (2012) <p>No additional information for the 2013 January - May period has been submitted</p>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : Help in Design Echocardiographic protocol (2012) - Merck Sharp & Dohme : Lecture (2012) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - FP7 EU research program : CV Imaging (2012) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer : ESC Textbook of CV Imaging (2012) <p>Additional Information declared for 2013 January - May</p> <p>13/05/2013 Same</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.